ArticleBMC nephrology2025
Urinary betaine/creatinine ratio enhances diagnostic accuracy of PLA2R-Ab in idiopathic membranous nephropathy.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe sensitivity of serum anti-phospholipase A2 receptor antibody (PLA2R-Ab) in diagnosing idiopathic membranous nephropathy (IMN) remains suboptimal, underscoring the need for complementary biomarkers, particularly in seronegative cases. This study aimed to identify urine metabolic signatures associated with IMN to improve diagnostic insight.
methodsUntargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) metabolomic profiling was performed on urine samples from IMN patients and healthy controls (HCs). Differential metabolites were identified using multivariate statistical analyses and further evaluated through metabolic network and pathway enrichment analyses. Key metabolites were subsequently validated using targeted metabolomics and ELISA in an extended cohort comprising 53 IMN patients (30 PLA2R-Ab positive and 23 PLA2R-Ab negative), 30 HCs, 23 patients with IgA nephropathy (IgAN), and 7 with minimal change nephropathy (MCN). Core metabolites were validated using 5-fold cross-validation.
resultsUntargeted metabolomics revealed 116 significantly altered metabolites in IMN patients. Enrichment analysis highlighted notable perturbations in pathways including Ferroptosis, Taurine and hypotaurine metabolism, and Glycine, serine, and threonine metabolism. Among eight quantitatively validated metabolites, urinary betaine was consistently elevated in IMN. The urinary betaine-to-creatinine ratio (Betaine/uCr) was significantly higher in the IMN group compared with HCs and IgAN patients (all p < 0.05), and was independent of common clinical parameters. Betaine/uCr alone discriminated IMN from HCs with an AUC of 0.83 and exhibited high specificity (96%) in distinguishing IMN from IgAN. Importantly, combining Betaine/uCr with PLA2R-Ab serology improved diagnostic performance (AUC = 0.91) compared to either marker alone. 5-fold cross-validation showed that the results were stable and reliable.
conclusionsUrinary metabolomics uncovered characteristic metabolic disturbances in IMN, involving pathways related to podocyte injury and osmotic regulation. The betaine/uCr showed preliminary potential as an auxiliary diagnostic marker when combined with PLA2R-Ab, though its specificity required further investigation. Therefore, broader studies are needed to establish its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.